Comparative Pharmacology
Head-to-head clinical analysis: HYPAQUE M 75 versus IOPAMIDOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYPAQUE M 75 versus IOPAMIDOL.
HYPAQUE-M,75% vs IOPAMIDOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast agent that attenuates X-rays, providing radiographic contrast due to high iodine content. It increases the density of vascular structures and tissues, allowing visualization of anatomical structures during imaging procedures.
Iopamidol is a nonionic, water-soluble radiographic contrast agent that attenuates X-rays by increasing the density of vascular structures and organs, thereby enhancing contrast in imaging studies. It does not have a pharmacological mechanism of action but exerts its effect via physical radiopacity.
1.2-1.5 mL/kg IV as a single dose for CT enhancement; maximum 150 mL per procedure.
Intravenous or intra-arterial administration; dose varies by procedure (e.g., cerebral angiography: 5-10 mL; coronary arteriography: 3-10 mL per injection; CT: 50-150 mL; adults: up to 200 mL total).
None Documented
None Documented
Terminal elimination half-life: 1.5-2 hours in normal renal function; prolonged in renal impairment (up to 24-48 hours in anuria).
2 hours; prolonged in renal impairment (up to 30 hours in anuria)
Renal excretion: >95% unchanged via glomerular filtration; biliary/fecal: <5%.
Renal: >90% unchanged; biliary/fecal: <2%
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent